Prophylaxis of the antiphospholipid syndrome: a consensus report

Abstract

Hypothetical circumstances that may require prophylaxis for a potential antiphospholipid syndrome (primary prophylaxis), or in some instances when there already had been some manifestations of the syndrome (secondary prophylaxis), were presented to a panel of experts for their consideration on potential prophylactic intervention. These were subsequently presented to the participants in the First InternationalConsensuson Treatment of the AntiphospholipidSyndrome. In most instances there was consensus in adding low dose aspirin, an exception being aspirin allergy when other antiaggregants could be used in nonpregnant subjects. General measures to prevent thrombosis and other vaso-protective actions should also be provided. Higher risk of fetal loss or thrombosis called for anticoagulation with coumadin in nonpregnant subjects or subcutaneous low molecular weight heparin in pregnant ones. When indicated, prophylaxis of the antiphospholipid syndrome should be provided in systemic lupus erythematosus patients who are being treated for their disease. In no instanceshould corticosteroidsor immunosuppresantsbe given as prophylacticof an antiphospholipid syndrome.

Keywords

anti-β-2-glycoprotein anticoagulation antiphospholipid antibodies low-dose aspirin pregnancy loss systemic lupus erythematosus thrombosis prevention

Get full access to this article

View all access options for this article.

References

Wahl DG , Bounameaux H , de Moerloose P , Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipidantibodies. Do the benefits outweigh the risks? A decision analysis . Arch Int Med 2000; 160: 2042-2048 .

Khamashta MA , Cuadrado MJ , Mujic F , Taub NA , Hunt BJ , Hughes GR. The management of thrombosis in the antiphospholipid antibody syndrome . New Engl J Med 1995; 332: 993-997 .

Ginsburg KS , Liang MH , Newcomer L , Goldhaber SZ , Schur PH , Hennekens CH , Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis . Ann Intern Med 1992, 117: 997-1002 .

Erkan D , Merrill JT , Yazici Y , Sammaritano L , Buyon JP , Lockshin MD. High thrombosis rate after fetal loss in APS: Effective prophylaxis with aspirin . Arthritis Rheum 2001; 44: 1466-1467 .

Erkan D , Yazici Y , Peterson MG , Sammaritano L , Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome . Rheumatology (Oxford) 2002; 41: 924-929 .

Petri M , Hellman D , Hochberg M , Meyerhoff J , Bell W , Goldman D. Arterial thrombotic events in SLE: The Baltimore Lupus Cohort Study . Arthritis Rheum 1994; 37: S297-S297 (abstract).

Gómez-Pacheco L , Villa AR , Drenkard C , Cabral AR , Alarcón-SegoviaD. Serum anti-B2-glycoprotein-I antibodies during thrombosis in systemic lupus erythematosus patients . Am J Med 1999; 106: 417-423 .

Galli M , Luciani D , Bertolini G , Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the antiphospholipidsyndrome: a systematic review of the literature . Blood (in press).

Blank M , Krause I , Fridkin M , Keller N , Kopolovic J , Goldberg I , Tobar A , Shoenfeld Y. Bacterial induction of autoantibodies to B2-glycoprotein-I accounts for the infectious etiology of antiphospholipidsyndrome . J Clin Invest 2002; 109: 797-804 .